Pacritinib

Routes of
administrationBy mouthATC codeLegal statusLegal status IdentifiersCAS NumberPubChem CIDDrugBankChemSpiderUNIIKEGGChEMBLPDB ligandChemical and physical dataFormulaC₂₈H₃₂N₄O₃Molar mass472.589 g·mol⁻¹3D model (JSmol)

Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis.^[1][2] It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).

Common side effects include diarrhea, low platelet counts, nausea, anemia, and swelling in legs.^[2]

Medical uses

Pacritinib in indicated to treat adults who have a rare form of a bone marrow disorder known as intermediate or high-risk primary or secondary myelofibrosis and who have platelet (blood clotting cells) levels below 50,000/µL.^[1][2]

History

The effectiveness and safety of pacritinib were demonstrated in a study that included 63 participants with intermediate or high-risk primary or secondary myelofibrosis and low platelets who received pacritinib 200 mg twice daily or standard treatment.^[2] Effectiveness was determined based upon the proportion of participants who had a 35% or greater spleen volume reduction from baseline to week 24.^[2] Nine participants (29%) in the pacritinib treatment group had a 35% or greater spleen volume reduction, compared to one participant (3%) in the standard treatment group.^[2]

The U.S. Food and Drug Administration (FDA) granted the application for pacritinib priority review, fast track, and orphan drug designations.^[2]

Society and culture

Names

Pacritinib is the International nonproprietary name (INN).^[3][4]

References

External links

• "Pacritinib". Drug Information Portal. U.S. National Library of Medicine.